Neeraja Recharla

Dr. Neeraja Recharla

Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
NRNeeraja Recharla
Neeraja Recharla
RGRamasatyaveni Geesala
Ramasatyaveni Geesala
XSXuan-Zheng Shi
Xuan-Zheng Shi
Background and objective: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder characterized by aberrant immune responses and compromised barrier function in the gastrointestinal tract. IBD is associated with altered gut microbiota and their metabolites in the colon. Butyrate, a gut microbial metabolite, plays a crucial role in regulating immune function, epithelial barrier function, and intestinal homeostasis. In this review, we aim to present an overview of butyrate synthesis and metabolism and the mechanism of action of butyrate in maintaining intestinal homeostasis and to discuss the therapeutic implications of butyrate in IBD. Methods: We searched the literature up to March 2023 through PubMed, Web of Science, and other sources using search terms such as butyrate, inflammation, IBD, Crohn’s disease, and ulcerative colitis. Clinical studies in patients and preclinical studies in rodent models of IBD were included in the summary of the therapeutic implications of butyrate. Results: Research in the last two decades has shown the beneficial effects of butyrate on gut immune function and epithelial barrier function. Most of the preclinical and clinical studies have shown the positive effect of butyrate oral supplements in reducing inflammation and maintaining remission in colitis animal models and IBD patients. However, butyrate enema showed mixed effects. Butyrogenic diets, including germinated barley foodstuff and oat bran, are found to increase fecal butyrate concentrations and reduce the disease activity index in both animal models and IBD patients. Conclusions: The current literature suggests that butyrate is a potential add-on therapy to reduce inflammation and maintain IBD remission. Further clinical studies are needed to determine if butyrate administration alone is an effective therapeutic treatment for IBD.

18 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
NRNeeraja Recharla
Neeraja Recharla
RGRamasatyaveni Geesala
Ramasatyaveni Geesala
XSXuan-Zheng Shi
Xuan-Zheng Shi
Intestinal commensal microbes, called the gut microbiota, play a critical role in host immune homeostasis through active microbial metabolites and innate and adaptive immune responses. Dysbiosis or imbalance of the gut microbiota composition is associated with inflammatory bowel disease (IBD) which includes Crohn’s disease and ulcerative colitis. The incidence and prevalence rates of IBD have been increasing worldwide. It is well recognized that butyrate, a microbial metabolite of diet fibers, is a major energy source for colonocytes and plays a crucial role in regulating immune function and maintaining epithelial barrier function and intestinal homeostasis. Emerging evidence suggests that butyrate might be a potential therapeutic agent to treat IBD. In this review, we discuss about gut microbial metabolites, particularly butyrate, the synthesis and metabolism of butyrate, mechanisms of butyrate in immune and epithelial barrier function. Furthermore, we review the current research on various therapeutic implications of butyrate in IBD.

22 October 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
RGRamasatyaveni Geesala
Ramasatyaveni Geesala
PGPratik Gongloor
Pratik Gongloor
NRNeeraja Recharla
Neeraja Recharla
XSXuan-Zheng Shi
Xuan-Zheng Shi
Background and Objectives: Crohn’s disease (CD) is an inflammatory bowel disease (IBD) characterized by transmural inflammation and intestinal fibrosis involving mostly the small intestine and colon. The pathogenic mechanisms of CD remain incompletely understood and cures are unavailable. Current medical therapies are aimed at inducing prolonged remission. Most of the medical therapies such as corticosteroids have substantial adverse effects. Consequently, many dietary therapies have been explored for the management of CD. Up to now, exclusive enteral nutrition (EEN) has been considered the only established dietary treatment for IBD, especially CD. In this article, we aim to give a concise review about the current therapeutic options and challenges in the management of CD and aim to compare the efficacy of EEN with other dietary therapies and update on the possible mechanisms of the benefits of EEN and other nutritional therapies. Methods: We searched the literature up to August 2024 through PubMed, Web of Science, and other sources using search terms such as EEN, nutritional therapy, IBD, Crohn’s disease, ulcerative colitis. Clinical studies in patients and preclinical studies in rodent models of IBD were included in the summary of the therapeutic benefits. Results and Conclusions: EEN involves oral or nasogastric tube feeding of a complete liquid diet with exclusion of normal foods for a defined period (usually 6 to 8 weeks). EEN treatment is demonstrated to have anti-inflammatory and healing effects in CD through various potential pathways, including altering gut bacteria and their metabolites, restoring the barrier function, direct anti-inflammatory action, and indirect anti-inflammatory action by eliminating mechanical stress in the bowel. However, efficacy of other nutritional therapies is not well established in CD, and mechanisms of action are largely unknown.

26 January 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
RGRamasatyaveni Geesala
Ramasatyaveni Geesala
NRNeeraja Recharla
Neeraja Recharla
KZKe Zhang
Ke Zhang
JJJohn Johnson
John Johnson
GGGeorge Golovko
George Golovko
XSXuan-Zheng Shi
Xuan-Zheng Shi
Exclusive enteral nutrition (EEN) is an established dietary treatment for Crohn’s disease (CD) by alleviating inflammation and inducing remission. However, the mechanisms of action of EEN are incompletely understood. As CD is associated with gut microbiome dysbiosis, we investigated the effect of EEN on the microbiome in a rat model of CD-like colitis. The rat model of CD-like colitis was established by an intracolonic instillation of TNBS at 65 mg/kg in 250 µL of 40% ethanol. Sham control rats were instilled with saline. Rats were fed ad libitum with either regular pellet food or EEN treatment with a clear liquid diet (Ensure). Rats were euthanized at 7 days. Fecal pellets were collected from the distal colon for 16S rRNA sequencing analysis of gut microbiota. In addition, colon tissues were taken for histological and molecular analyses in all the groups of rats. EEN administration to TNBS-induced CD rats significantly improved the body weight change, inflammation scores, and disease activity index. The mRNA expression of IL-17A and interferon-γ was significantly increased in the colonic tissue in TNBS rats when fed with regular food. However, EEN treatment significantly attenuated the increase in IL-17A and interferon-γ in TNBS rats. Our 16S rRNA sequencing analysis found that gut microbiota diversity and compositions were significantly altered in TNBS rats, compared to controls. However, EEN treatment improved alpha diversity and increased certain beneficial bacteria such as Lactobacillus and Dubosiella and decreased bacteria such as Bacteroides and Enterorhabdus in CD-like rats, compared to CD-like rats with the regular pellet diet. In conclusion, EEN treatment increases the diversity of gut microbiota and the composition of certain beneficial bacteria. These effects may contribute to the reduced inflammation by EEN in the rat model of CD-like colitis.

3 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
KZKe Zhang
Ke Zhang
JJJohn Johnson
John Johnson
SSSena Saygili
Sena Saygili
DSDaniel Shi
Daniel Shi
NRNeeraja Recharla
Neeraja Recharla
XSXuan-Zheng Shi
Xuan-Zheng Shi
Background and Aims: Postoperative ileus (POI) is a motility dysfunction associated with inflammation in the gastrointestinal (GI) tract after abdominal surgery. Management relies on supportive care, as there is no effective medical treatment. Clinical trials found that coffee consumption improves bowel movement and shortens hospital stays in POI. We aimed to investigate the mechanisms underlying the beneficial effect of coffee in an animal model of POI. Methods: Mouse POI was established by manipulation of the small intestine with wet swab applicators for 5 min. Mice were then treated with water, regular or decaffeinated coffee (10 mg per day) by oral gavage and euthanized 24 h after the operation. Key Results: Intestinal manipulation slowed GI transit rate from 5.64 ± 0.47 to 3.77 ± 0.16 (N = 6, measured by geometric center), reduced intestinal muscle contractility, and induced an acute inflammatory response with increased expression of proinflammatory mediators such as IL-6, IL-1, CCL2, and CXCL-1 in the POI intestine. Coffee treatment (regular or decaffeinated) did not reduce inflammation or the expression of inflammatory mediators but significantly improved muscle contractility and increased GI transit to 4.59 ± 0.31 (N = 5) and 4.80 ± 0.29 (N = 5) in POI mice (regular and decaffeinated coffee, respectively). Regular or decaffeinated coffee dose-dependently (0.1–10 mg/mL) increased contractility of intestinal muscle strips. The contractile effect was not affected by neural toxin tetrodotoxin (10−6 M) or cholinergic nicotinic antagonist hexamethonium (10−4 M) but was completely abolished by muscarinic receptor antagonist atropine (10−6 M). Conclusions: Coffee consumption does not attenuate inflammatory response but improves GI motor function and stimulates intestinal smooth muscle contractions in the mouse model of POI. Coffee stimulates contractions in a caffeine-independent manner through a cholinergic muscarinic receptor-dependent mechanism.